Good
Mostly Aligned
Patient Risk:
Low
Summary
Most statements align with the label’s general indication for endometriosis-associated pain and the limitation that duration is constrained due to bone loss. However, the response makes specific symptom-type assertions (e.g., dyspareunia; pelvic pain not related to menstruation) that are not explicitly supported by the provided label excerpts, and it asserts a mechanism not supported in the supplied text.
Category Scores
Accurate Statements
Orilissa (elagolix) is used to treat painful symptoms related to endometriosis.
Supported by Section 1: ORILISSA is indicated for management of moderate to severe pain associated with endometriosis.
Orilissa is prescribed for endometriosis pain including pain with menstruation (dysmenorrhea).
Supported indirectly by Section 14 defining responders as including reduction in dysmenorrhea and non-menstrual pelvic pain.
Orilissa is aimed at symptom control.
Consistent with Section 1 (management of pain) and Section 14 responder definition focusing on reduction in dysmenorrhea and non-menstrual pelvic pain.
Orilissa does not cure endometriosis.
No cure/curative claim is stated in the provided excerpts; the statement is not contradicted by the label excerpts provided.
The key labeled use of Orilissa is treatment of endometriosis-related pain.
Supported by Section 1 indication for management of moderate to severe pain associated with endometriosis.
Unsupported Statements
Orilissa works by lowering estrogen-related activity that can drive endometriosis pain.
The provided label excerpts do not describe this estrogen-activity mechanism.
Orilissa is prescribed for endometriosis pain including pelvic pain not related to menstruation.
While Section 14 mentions non-menstrual pelvic pain in defining responders, the provided excerpts do not explicitly state this as a labeled symptom category in the Indications section.
Orilissa is prescribed for endometriosis pain including pain during or after sex (dyspareunia).
The provided label excerpts do not mention dyspareunia.
Contradictions
Important Omissions
Important labeled limitations on duration of use (based on dose and bone loss), and pregnancy exclusion timing/requirements before starting.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The response primarily describes labeled indication and symptom-management intent. It does not provide dosing, contraindication, or interaction instructions that could directly cause harm, but it includes an unsupported mechanism claim and omits key labeled safety limitations (duration/bone loss considerations; pregnancy-related requirements).
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Unsupported mechanistic claim and specific symptom-type statements (notably dyspareunia) not present in the provided label excerpts; omission of labeled duration/pregnancy-related limitations.
Suggested Improvement
Restrict symptom descriptions to those explicitly supported by the provided excerpts (e.g., dysmenorrhea and non-menstrual pelvic pain as reflected in Section 14) and remove/avoid the estrogen-activity mechanism claim unless present in the supplied label text. Include the labeled limitation on duration of use due to bone loss and pregnancy-related initiation/discontinuation guidance.